Literature DB >> 11926411

Tumor-induced death of immune cells: its mechanisms and consequences.

Theresa L Whiteside1.   

Abstract

FasL is a death-inducing as well as pro-inflammatory molecule. The seemingly opposing consequences of Fas/FasL interactions appear to be dependent on the context of the tumor or tissue microenvironment. The term 'contextual' has been coined to describe cellular and molecular events that may be opposing, yet are mediated by the engagement of the same receptor-ligand pair. Because Fas is one of the death-inducing receptors, its ligand is dangerous. Hence, the availability of FasL for cross-linking of the receptor has to be extremely carefully regulated. Different levels of control appear to exist, some involving cell membrane-associated MMPs and others depending on cytokines released from neighboring cells. In tumors, which shape their microenvironment to make it unwelcome to immune effector cells, FasL is used to kill infiltrating cells without damage to the tumor, which develops multiple means of hiding/inhibiting the death pathway. On the other hand, in situations provoking inflammatory responses such as allograft rejection, infection, and tissue necrosis, FasL assumes the role of attractant for inflammatory cells. In these situations, FasL acts in conjunction with other cytokines, and its effects might be modified in the context of unfolding events. When put in the context of biologic interactions that take place at the tumor site, the Fas/FasL pathway emerges as a molecular mechanism, which contributes to immune privilege and tumor escape, but which can also enhance anti-tumor inflammatory responses. FasL, like many cytokines, is pleiotropic. It is also worth bearing in mind that other molecular players, including the other known members of the TNF family, almost certainly participate in establishing immune privilege status of tumors. While a broad body of new information has contributed to clarifying the dual role of FasL in the tumor biology, much remains to be learned about molecular mechanisms that control its effects in the tumor and in normal tissues.

Entities:  

Mesh:

Year:  2002        PMID: 11926411     DOI: 10.1006/scbi.2001.0402

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  38 in total

Review 1.  Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy.

Authors:  Arvind Chhabra
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic.

Authors:  Malgorzata Czystowska; Miroslaw J Szczepanski; Marta Szajnik; Karen Quadrini; Harvey Brandwein; John W Hadden; Theresa L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2010-12-23       Impact factor: 6.968

Review 3.  Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors:  Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Fine-tuning anti-tumor immunotherapies via stochastic simulations.

Authors:  Giulio Caravagna; Roberto Barbuti; Alberto d'Onofrio
Journal:  BMC Bioinformatics       Date:  2012-03-28       Impact factor: 3.169

5.  Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.

Authors:  Li-Ning Xu; Sheng-Quan Zou; Jian-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

Review 6.  Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions.

Authors:  Julia Kravchenko; Emanuela Corsini; Marc A Williams; William Decker; Masoud H Manjili; Takemi Otsuki; Neetu Singh; Faha Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson; Leroy Lowe; H Kim Lyerly
Journal:  Carcinogenesis       Date:  2015-05-22       Impact factor: 4.944

7.  Multiparametric immune profiling in HPV- oral squamous cell cancer.

Authors:  Zipei Feng; Daniel Bethmann; Matthias Kappler; Carmen Ballesteros-Merino; Alexander Eckert; R Bryan Bell; Allen Cheng; Tuan Bui; Rom Leidner; Walter J Urba; Kent Johnson; Clifford Hoyt; Carlo B Bifulco; Juergen Bukur; Claudia Wickenhauser; Barbara Seliger; Bernard A Fox
Journal:  JCI Insight       Date:  2017-07-20

Review 8.  Metabolic reprogramming and apoptosis sensitivity: Defining the contours of a T cell response.

Authors:  Kelsey Voss; Sasha E Larsen; Andrew L Snow
Journal:  Cancer Lett       Date:  2017-09-01       Impact factor: 8.679

Review 9.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

10.  Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer.

Authors:  Andreas E Albers; Carsten Schaefer; Carmen Visus; William Gooding; Albert B DeLeo; Theresa L Whiteside
Journal:  Head Neck       Date:  2009-06       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.